Cancer Stem Cell targeted Liposome Delivery System Design Service
Creative Biolabs utilizes these deep scientific insights to engineer advanced lipid-based carriers that are specifically optimized to penetrate this CSC niche. By integrating stimuli-responsive lipids that react to the acidic or hypoxic conditions of the tumor core, we ensure that therapeutic payloads are released precisely where they are needed most. Furthermore, our platform leverages high-affinity surface functionalization, utilizing antibodies, aptamers, and peptides, to facilitate receptor-mediated internalization. This dual-action approach not only improves the delivery of conventional drugs but also enables the effective transport of regulatory inhibitors and epigenetic modifiers. By targeting the regenerative core of the tumor, our custom-designed liposomes provide a robust strategy for overcoming multidrug resistance and ensuring long-term therapeutic durability.
Scientific Foundation: Overcoming the CSC Barrier in Oncology
The CSC hypothesis has redefined oncology by identifying resilient subpopulations that drive tumor recurrence and metastasis. While conventional chemotherapies debulk primary tumors, they often spare quiescent CSCs, which possess unique self-renewal and differentiation potential. Designing targeted liposomal delivery systems is a critical evolution, as CSCs reside within protective, hypoxic microenvironmental niches characterized by dense extracellular matrix and unique metabolic profiles. By focusing on these "seeds" of relapse rather than just bulk mass, advanced nanomedicines can penetrate these biological fortifications to overcome intratumoral heterogeneity and chemotherapeutic failure, ensuring total tumor clearance.
Technical Specifications and Custom Modules
Active Targeting Modules
We provide conjugation services for a diverse array of targeting moieties, including monoclonal antibodies, scFv fragments, and high-affinity aptamers specific to markers like CD44, CD133, and EpCAM.
Stimuli-Responsive Lipids
Integration of "smart" components such as pH-sensitive lipids for endosomal escape and hypoxia-responsive azo-linkers that trigger drug release in the oxygen-deprived CSC niche.
Dual-Payload Co-Encapsulation
Design of systems capable of carrying both a traditional chemotherapeutic (to reduce tumor bulk) and a CSC-specific sensitizer (to prevent recurrence).
Characterization & Validation
Comprehensive analytical packages featuring dynamic light scattering (DLS), transmission electron microscopy (TEM), and encapsulation efficiency (EE%) quantification.
Maximize Therapeutic Efficacy — Explore Our Technical Modules & Get an Expert Assessment
Workflow
Creative Biolabs has established a streamlined, collaborative workflow designed to translate your therapeutic concepts into high-performance liposomal delivery systems.
Publication
This study presents a novel redox-responsive liposome (CEP-LP@S/D) that co-delivers doxorubicin and salinomycin to synergistically target and eliminate liver CSCs. The system uses a Y-shaped peptide targeting both CD133 and EpCAM for selective CSC uptake, followed by glutathione-triggered drug release. In vitro and in vivo results demonstrate enhanced tumor accumulation, potent cytotoxicity, and effective CSC eradication, offering a promising strategy against hepatocellular carcinoma.
Fig.1 Schematic depiction of controlled drug delivery via a GSH-responsive CEP-LP@S/D liposomal system. 1
Why Choose Us?
Creative Biolabs stands at the forefront of oncology-focused nanomedicine. Our unique advantages are grounded in scientific excellence and a proven track record of overcoming multidrug resistance (MDR) in preclinical models.
Extensive Ligand Library
We possess one of the industry's most comprehensive catalogs of validated CSC-targeting moieties, including rare markers like CD117 and Lgr5.
Advanced Redox Modulation
Our designs incorporate the latest research in antioxidant restoration (restoring SOD and CAT levels) to sensitize CSCs to reactive oxygen species (ROS)-inducing therapies.
Epigenetic Integration
We offer unique expertise in the liposomal delivery of DNA methyltransferase (DNMT) inhibitors, which have been shown to "re-program" the CSC epigenome for improved therapeutic response.
Published Efficacy
Based on internal benchmarks and published data, our targeted delivery systems consistently show up to a 10-fold increase in intracellular concentration within the CSC subpopulation compared to non-targeted equivalents.
Experience the Creative Biolabs Advantage — Optimize Your Delivery System & Get a Custom Quote Today
FAQs
Can your liposomes bypass the blood-brain barrier (BBB) for brain CSCs?
Yes, we can incorporate specific ligands (e.g., transferrin or angiopep-2) alongside CSC-targeting markers to facilitate BBB crossing and niche engagement.
What types of payloads are compatible with your system?
Our platform is highly versatile, supporting everything from hydrophobic small molecules and peptides to hydrophilic nucleic acids (siRNA/mRNA).
How do you minimize the immune response to the liposomes?
We use "stealth" technology (PEGylation) and biocompatible, endogenous-like phospholipids to ensure minimal immunogenicity and maximal circulation time.
Customer Review
-
Exceptional Stability and EE%
The decitabine-loaded liposomes facilitated the re-sensitization of our resistant lung cancer lines. The stability of the PEGylated formulation was impressive for our long-term pharmacokinetic studies, and the characterization report was incredibly thorough. - Prof. M***el L -
Breakthrough in 3D Modeling
The HA-coated liposomes provided by Creative Biolabs improved our 3D spheroid penetration by 4x compared to our previous attempts. Their technical support was vital in adjusting the zeta potential for our specific media conditions. - Sarah J****n
Related Services
Cancer Stem Cell targeted Antibody modified Nanoparticle Development
Creative Biolabs provides CD44/CD133-targeted platforms to eliminate quiescent CSCs. By bypassing ABC efflux transporters, our smart systems ensure total tumor clearance and prevent recurrence.
Learn More →Tumor Profiling in Endometrial Cancer
Creative Biolabs provides endometrial tumor profiling using single-cell and multi-omics technologies. We analyze biomarkers to explore TME heterogeneity, accelerating prognostic analysis and personalized immunotherapy development with high accuracy.
Learn More →How to Contact Creative Biolabs
Creative Biolabs provides a data-driven, highly customizable cancer stem cell targeted liposome delivery system design service that targets the fundamental causes of tumor relapse. By combining advanced lipid chemistry with deep expertise in stem cell biology, we provide a robust pathway for the development of curative cancer therapies.
Collaborate with Our Specialists — Contact Our Team for More Information and to Discuss Your Project
Reference
- Wang, Z., et al. "A Novel CD133- and EpCAM-Targeted Liposome With Redox-Responsive Properties Capable of Synergistically Eliminating Liver Cancer Stem Cells." Front Chem 8 (2020): 649. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fchem.2020.00649
Download our brochure